We used the nationwide claims database to calculate the incidence of thrombotic events and predict their overall 2-week incidence. From 2006 to 2020, the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) tended to increase. Unlike intracranial venous thrombosis (ICVT) and intracranial thrombophlebitis (ICTP), which showed no age difference, other venous embolism, and thrombosis (OVET), DIC, DVT, and PE were significantly more common in over 65 years. The overall 2-week incidence of ICVT was 0.21/1,000,000 (95% confidence interval [CI], 0.11-0.32). ICTP, OVET, DIC, DVT and PE were expected to occur in 0.08 (95% CI, 0.02-0.14), 7.66 (95% CI, 6.08-9.23), 5.95 (95% CI, 4.88-7.03), 13.28 (95% CI, 11.92-14.64), 14.09 (95% CI, 12.80-15.37) per 1,000,000, respectively. To date, of 8,548,231 patients vaccinated with ChAdOx1 nCoV-19 in Korea, two had confirmed thrombosis with thrombocytopenia syndrome within 2 weeks. The observed incidence of ICVT after vaccination was 0.23/1,000,000.

中文翻译：

---

接种 ChAdOx1 nCoV-19 疫苗的韩国人血栓栓塞事件的预测和观察发生率。

我们使用全国索赔数据库来计算血栓事件的发生率并预测其整体 2 周发生率。2006-2020年，深静脉血栓形成（DVT）、肺栓塞（PE）和弥散性血管内凝血（DIC）的发病率呈上升趋势。与无年龄差异的颅内静脉血栓形成 (ICVT) 和颅内血栓性静脉炎 (ICTP) 不同，其他静脉栓塞和血栓形成 (OVET)，DIC、DVT 和 PE 在 65 岁以上明显更常见。ICVT 的总体 2 周发生率为 0.21/1,000,000（95% 置信区间 [CI]，0.11-0.32）。ICTP、OVET、DIC、DVT 和 PE 预计发生在 0.08 (95% CI, 0.02-0.14), 7.66 (95% CI, 6.08-9.23), 5.95 (95% CI, 4.88-7.03), 13.28 (958) % CI, 11.92-14.64), 14.09 (95% CI, 12.80-15.37) 每 1,000,000 人。迄今为止，在 8,548 人中，在韩国接种了 ChAdOx1 nCoV-19 的 231 名患者，其中两人在 2 周内确诊血栓形成并伴有血小板减少综合征。接种疫苗后观察到的 ICVT 发生率为 0.23/1,000,000。